Controlling LCN2, associated with astrocytes, might offer a potential solution for treating depression, as current LCN2-targeted treatment methods include targeted drug delivery to mitigate its overexpression and interaction with astrocytes, thereby potentially reducing neuroinflammation and enhancing neurological recovery [39]. Here, LCN2 is linked to major depressive disorder.